DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI - DISCOVERED THERAPEUTIC CANDIDATE
Artificial Intelligence enables target and drug candidate to be identified in less than 18 months. Initial target of Wilson disease represents significant clinical need, new era of drug discovery.
Toronto, Ontario – September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.
“This is ...